Date: 2017-07-18
Type of information: Nomination
Compound: Vice President Scientific Affairs, Europe
Company: Audentes Therapeutics (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On July 18, 2017, Audentes Therapeutics announced the appointment of Fulvio Mavilio, Ph.D. to Vice President Scientific Affairs, Europe. Dr. Mavilio will be based in Paris. Prior to joining Audentes, Dr. Mavilio served as Scientific Director of Genethon, Evry, France (2012-2017). Prior to that he was co-Director of the Center for Regenerative Medicine of the University of Modena, Italy (2006-2011), Director of Discovery of Molmed (2002-2005), founder and Chief Scientific Officer of Genera (1999-2002), and co-Director of the San Raffaele-Telethon Institute of Gene Therapy in Milan, Italy (1995-2002). Dr. Mavilio is a member of the European Molecular Biology Association (EMBO), Member of the Board of the American Society of Gene and Cell Therapy (ASGCT), and a member of the Editorial Board of many international journals in the fields of genetics, molecular biology and gene therapy. He graduated in Biology at the University of Rome in 1976, obtained a Ph.D. in Medical Genetics at the School of Medicine of the same University in 1979, and trained as a visiting scientist at the Wistar Institute in Philadelphia, PA from 1985 to 1989. An expert and a pioneer in the fields of gene therapy and stem cell research, Dr. Mavilio has published over 170 articles in major international journals. He also serves as Professor of Molecular Biology at the University of Modena and Reggio Emilia (Modena, Italy).
Financial terms:
Latest news:
Is general: Yes
